Cigna’s first quarter results reflected momentum in its core health services and specialty pharmacy businesses, as management highlighted strong demand for specialty drugs and continued investment in technology. CEO David Cordani cited improvements in operational efficiency and customer-focused initiatives, such as streamlining prior authorizations and leveraging AI to enhance patient engagement. Specialty and Care Services, in particular, saw robust adoption of biosimilars and specialty generics, which management pointed to as key factors supporting margin stability and cost management. CFO Ann Dennison noted that lower flu volumes and weather-related care deferrals also contributed to favorable medical cost trends for the quarter.
Is now the time to buy CI? Find out in our full research report (it’s free for active Edge members).
Cigna (CI) Q1 CY2026 Highlights:
- Revenue: $68.52 billion vs analyst estimates of $66.5 billion (4.7% year-on-year growth, 3% beat)
- Adjusted EPS: $7.79 vs analyst estimates of $7.61 (2.4% beat)
- Adjusted EBITDA: $3.15 billion vs analyst estimates of $3.21 billion (4.6% margin, 2% miss)
- Management slightly raised its full-year Adjusted EPS guidance to $30.35 at the midpoint
- Operating Margin: 3.4%, in line with the same quarter last year
- Customers: 16.62 million, up from 16.42 million in the previous quarter
- Market Capitalization: $74.59 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Cigna’s Q1 Earnings Call
- Albert Rice (UBS): Asked about transition timing and client uptake for the new Signature pharmacy model. President and COO Brian Evanko explained the model becomes standard in 2028, with positive early client feedback and a clear path to broad adoption.
- Kevin Fischbeck (Bank of America): Inquired about capital redeployment following the exit from the individual exchange business and the eviCore strategic review. Evanko clarified these were proactive steps to intensify focus on core growth platforms and that capital freed would not be material in the near-term.
- Lisa Gill (JPMorgan): Sought details on cost cadence and specialty business growth drivers. CFO Ann Dennison cited strong specialty volume, biosimilar adoption, and contributions from recent investments as key factors behind segment outperformance.
- Charles Rhyee (TD Cowen): Asked about biosimilar strategy and synergies between Evernorth business units. CEO Cordani and Evanko outlined how targeted formulary changes and AI-enabled patient conversion strategies are driving biosimilar uptake and cost savings.
- David Windley (Jefferies): Questioned GLP-1 program adoption and employer demand. Evanko noted stable employer coverage rates, growing program enrollment, and highlighted the ongoing tension between drug affordability and plan sponsor satisfaction.
Catalysts in Upcoming Quarters
In the coming quarters, our analyst team will be tracking (1) the pace of client transitions to the Signature pharmacy benefit model and feedback on its impact, (2) progress on portfolio reshaping, specifically any developments regarding the eviCore strategic review and exit from the individual exchange market, and (3) ongoing adoption rates and profitability within the specialty pharmacy segment, especially biosimilars and partnerships with hospitals. We will also pay close attention to the impact of AI-driven tools on cost trends and customer retention.
Cigna currently trades at $282.35, down from $292.32 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
